NEW YORK (GenomeWeb News) - Affymetrix and Invitrogen said today that Invitrogen has obtained a non-exclusive, worldwide license to a number of Affymetrix patents.
Under the agreement, Invitrogen will now be allowed to "manufacture and sell spotted nucleic acid microarrays in the research field," the companies said. Financial details of the license were not disclosed.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.